

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau**B109**

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: <b>A61K 31/155</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/12483</b> (43) International Publication Date: <b>2 May 1996 (02.05.96)</b>
(21) International Application Number: <b>PCT/US95/13788</b> (22) International Filing Date: <b>25 October 1995 (25.10.95)</b> (30) Priority Data: <b>08/328,925</b> <b>25 October 1994 (25.10.94)</b> <b>US</b> (60) Parent Application or Grant (63) Related by Continuation <b>US</b> <b>08/328,925 (CIP)</b> <b>Filed on</b> <b>25 October 1994 (25.10.94)</b> (71) Applicant (for all designated States except US): <b>WASHINGTON UNIVERSITY [US/US]; One Brookings Drive, St. Louis, MO 63130 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>WILLIAMSON, Joseph, R. [US/US]; 1611 Kriste Court, St. Louis, MO 63131 (US). CORBETT, John, A. [US/US]; Apartment 312, 6605 Clayton Avenue, St. Louis, MO 63139 (US). McDANIEL, Michael, L. [US/US]; 820 Warwick Lane, St. Louis, MO 63122 (US). TILTON, Ronald, G. [US/US]; 3110 Williams Glen, Sugarland, TX 77479 (US).</b>	(74) Agents: <b>HOLLAND, Donald, R. et al.; Howell &amp; Haferkamp, L.C., Suite 1400, 7733 Forsyth Boulevard, St. Louis, MO 63105-1817 (US).</b>  (81) Designated States: <b>AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SE, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).</b>  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: <b>METHOD OF INHIBITING NITRIC OXIDE FORMATION</b>		
(57) Abstract		
<p>A method is disclosed for inhibiting nitric oxide formation in a warm blooded mammal afflicted with an acute or chronic inflammatory disease which comprises administering to said mammal an effective nitric oxide inhibitory amount of methyl-, or 1,1-dimethyl-, or amino-substituted guanidines.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## METHOD OF INHIBITING NITRIC OXIDE FORMATION

This work was supported in part by National Institutes of Health grants DK06181, T32, DK07297, EY006600, HL39934, and DK20579.

### CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 This is a continuation-in-part of application Serial No. 08/328,925 filed October 25, 1994, which is in turn, a continuation-in-part of application Serial No. 08/110,915, filed August 24, 1993 a continuation-in-part of application Serial No. 07/843,387, filed February 28, 1992 and application Serial No. 07/906,632, filed June 30, 1992, each of which are a continuation-in-part of application Serial No. 10 07/807,912, filed December 16, 1991.

### BACKGROUND OF THE INVENTION

- This invention relates to a method of-inhibiting nitric oxide formation in warm blooded mammals and, more particularly, to the administration of methyl-, dimethyl-, or amino-substituted guanidines as inhibitors of nitric oxide production 15 in a host afflicted with acute or chronic inflammatory disease.

- Nitric oxide synthase catalyzes the mixed functional oxidation of L-arginine to L-citrulline and nitric oxide ( $\text{NO}^*$ ) [Stuehr et al., Proc. Natl. Acad. Sci. USA 88, 7773 (1991)].  $\text{NO}^*$  appears to function as either a signaling or an effector molecule depending on the isoform of the enzyme. The constitutive 20 isoform of nitric oxide synthase produces small amounts of  $\text{NO}^*$  which activate guanylate cyclase resulting in the formation of cGMP which mediates endothelium-dependent relaxation [Moncada et al., Pharmacol. Reviews 43, 109 (1991)] and neural transmission [Garthwaite, Trends Neurol. Sci. 14, 60 (1991)].  $\text{NO}^*$  is produced in much larger amounts by the cytokine and endotoxin inducible 25 isoform of nitric oxide synthase, and in macrophages functions as an effector molecule which appears to mediate the cytotoxic actions of macrophages on target cells [Hibbs et al., Nitric Oxide from L-Arginine: A Bioregulatory System, S.

Moncada and E. Higgs, Eds. Elsevier, NY, pp. 189-223 (1990)]. Since NO<sup>•</sup> is a potent vasodilator and increases blood flow, and since vasoactive agents (such as histamine and bradykinin), which stimulate NO<sup>•</sup> production increase both blood flow and vascular permeability, NO<sup>•</sup> may be a candidate for mediating increases in blood flow and vascular permeability induced by diabetes and elevated glucose [Pugliese et al., Diabetes/Metabolism Reviews 7, 35 (1991)].

Recently, Interleukin-1 (IL-1) has been shown to induce the expression of the cytokine inducible isoform of nitric oxide synthase in pancreatic islets. The production of NO<sup>•</sup> has been proposed to be the effector molecule which mediates IL-1's inhibitory effects on islet function [Southern et al., FEBS. Lett. 276, 42 (1990) and Corbett et al., Biochemical J. 287, 229 (1992)]. Generation of an IL-1-induced EPR detectable iron-nitrosyl complex, which is prevented by N<sup>G</sup>-monomethyl-L-arginine (NNMA), has been used to confirm the formation of nitric oxide by islets [Corbett et al., J. Biol. Chem. 266, pp. 21351-21354 (1991)]. Also, the protein synthesis inhibitor, cycloheximide has been shown to block IL-1-induced nitrite formation, cGMP accumulation, and EPR detectable iron-nitrosyl complex formation by islets, thus establishing that IL-1 induces the cytokine inducible isoform of nitric oxide synthase in pancreatic islets [Corbett et al., Biochemical J. 287, 229 (1992)].

The pathogenesis of diabetic complications has been linked to imbalances in sorbitol, myo-inositol, and 1,2-diacyl-sn-glycerol metabolism, and to non-enzymatic glycation of cellular and extracellular constituents [Pugliese et al., Diabetes/Metabolism 35 Reviews 7, 37 (1991)]. The glycation link is supported by evidence that aminoguanidine, a nucleophilic hydrazine compound, interferes with the formation of these glycation products and also attenuates the development of several diabetes-induced vascular [Pugliese et al., Diabetes/Metabolism Reviews 7, 35 (1991); Williams et al., Diabetes & Metab. 16, 3369 (1990); Soulis-Liparota et al., Diabetes 40, 1328 (1991)], neural [Kihara et al., Proc. Natl. Acad. Sci. USA 88, 6107 (1991)] and collagen changes [Brownlee et al., New Engl. J. Med. 318,

1315 (1988) and Brownlee et al., Science 232, 1629 (1986)]. Bucala et al., J. Clin. Invest. 87, 432 (1991) recently, reported that quenching of NO<sup>•</sup> in vitro by glycated albumin is attenuated by aminoguanidine (present during exposure of albumin to glycation agents) and suggested that glycation products may impair  
5 endothelium-dependent relaxation by attenuating NO<sup>•</sup> activity.

### BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention a novel method of inhibiting nitric oxide formation in warm blooded mammals afflicted with acute or chronic inflammatory diseases is provided. The method comprises administering to warm  
10 blooded mammals afflicted with acute or chronic inflammatory diseases a small but nitric oxide inhibitory effective amount of methyl-, dimethyl-, or amino-substituted guanidines. These inhibitory compounds are also chemically named as aminoguanidine, N, N' -diaminoguanidine, methylguanidine and 1, 1-dimethylguanidine.

15 It will be understood that pharmaceutically acceptable salts of these compounds, e.g., the HCl, HCO<sub>3</sub>, and sulfate salts, can also be administered to the host in accordance with the method of the invention. Inflammation can be conveniently divided into acute and chronic conditions. Acute inflammation is generally of relatively short duration and lasts for about a few minutes to about one to two  
20 days. Its main characteristics are increased blood flow, exudation of fluid and plasma proteins (edema) and emigration of leukocytes, predominantly neutrophils. Chronic inflammation is of longer duration and is associated histologically with the presence of lymphocytes and macrophages and with proliferation of blood vessels and connective tissue. Inflammation is manifested by heat, redness, swelling, pain  
25 and loss of function. See, e.g., Cotran, Kumar and Robbins, Robbins Pathologic Basis of Disease, 4th ed., W. B. Saunders Company, pp. 40-41 (1989); Chandrasoma and Taylor, Concise Pathology, First Edition, pp. 35-44, Appleton & Lange (1991).

The causes of inflammation are numerous and include such factors as microbial infections (e.g., bacterial and fungal infections), physical agents such as burns, radiation and trauma, chemical agents such as toxins and caustic substances, necrotic tissue and various types of immunologic reactions.

- 5 The present invention is directed to the prevention/treatment of a broad spectrum of diseases which may be linked to the production of nitric oxide by leukocytes (neutrophils and macrophages) and other cells of nonhemopoietic origin as distinguished from diseases mediated by immunologic reactions as claimed in  
10 copending application Serial No. 07/906,632. The treatment of acute inflammatory disease is illustrated herein in greater detail against endotoxin-induced acute uveitis and generalized vascular leakage and against inflammatory bowel disease.

- In these illustrative treatments, standard state-of-the-art animal models are used. The endotoxin-induced uveitis model in the rat is as described by Cousins et al., *Exo. Eve Res.* 39, 665-676 (1984); Herbolt et al., *Graefe's Arch. Clin. Exo. Ophthalmol.* 226, 553-558 (1988). The rat model for inflammatory bowel disease  
15 is a modification of that described by Hirono et al., *J. Natl. Cancer Inst.* 66, 579-583 (1981). However, it will be understood that the method of the invention is not limited to the treatment of uveitis or the treatment of inflammatory bowel disease, but includes treatment of other acute and chronic inflammatory diseases as  
20 mentioned above. These diseases include but are not limited to diseases such as, for example, acute and chronic infections (bacterial and fungal, including diphtheria and pertussis); acute and chronic bronchitis, sinusitis, and upper respiratory infections, including the common cold; acute and chronic gastroenteritis and colitis; acute and chronic cystitis) and urethritis; acute and chronic dermatitis; acute and  
25 chronic conjunctivitis; acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis and tendinitis); uremic pericarditis; acute and chronic cholecystitis; acute and chronic vaginitis; drug reactions; insect bites; burns (thermal, chemical, and electrical); and sunburn.

The present invention is likewise applicable to the treatment of a variety of inflammatory disease states including infectious diseases where active infection exists at any body site, such as in the instance of meningitis. Also included are conditions such as secondary infections that may occur at a site of antigen deposition that is secondary to a primary infection at a distant body site, and exemplary specific conditions would include meningitis, encephalitis, arthritis, and skin conditions such as psoriasis, whether acute or chronic; eczema; contact dermatitis; poison ivy; poison oak; poison sumac; and like inflammation-mediated conditions. Also included is the inflammation that results from alterations in leukocyte movement during infection such as adult respiratory distress syndrome associated with sepsis.

Other inflammatory disease states include those associated with immune disorders including involvement with T-cell and/or macrophage attachment/recognition, such as acute and delayed hypersensitivity, graft vs. host disease; auto-immune conditions such as pernicious anemia, Type I diabetes mellitus, rheumatoid arthritis and multiple sclerosis; antigen-antibody complex mediated diseases including certain of the secondary infection states listed above; and transplant rejection. Inflammation due to toxic shock or trauma such as adult respiratory distress syndrome and reperfusion injury; is likewise included within the scope hereof.

20

### DETAILED DESCRIPTION OF THE INVENTION

While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter regarded as forming the present invention, it is believed that the invention will be better understood from the following detailed description of preferred embodiments of the invention taken in conjunction with the accompanying drawings in which briefly:

25

FIG. 1 is a bar graph which shows the effect of increasing dose of lipopolysaccharide (LPS; endotoxin purified from *Salmonella minnesota*) on

regional  $^{125}\text{I}$ -albumin permeation (normalized to controls). The fold increase (from 0 to in excess of 4-fold increase) over controls is shown on the y axis for various tissues indicated on the x axis at three levels of LPS, namely 50  $\mu\text{g}$ , 100  $\mu\text{g}$  and 200  $\mu\text{g}$  LPS as a divided dose injected into both hind footpads of Lewis rats.

- 5 FIG. 2 is a bar graph which shows the effect of 35 endotoxin dose on regional blood flow changes. Blood flow changes in ml/min/g wet weight are shown as a fold increase (from 0 to in excess of 1.5-fold increase) on the y axis for various tissues indicated on the x axis at two levels of LPS, namely 100  $\mu\text{g}$  and 200  $\mu\text{g}$  LPS as a divided dose injected in Lewis rats as in FIG. 1.
- 10 FIG. 3 in four parts, FIGS. 3A, 3B, 3C and 3D, is a graphical representation which shows aqueous fluid leukocyte cell counts in Lewis rats treated with 100  $\mu\text{g}$  LPS. Cell counts of the aqueous fluid (FIG. 3A) and of three types of infiltrating cells into the aqueous fluid (FIG. 3B, lymphocytes; FIG. 3C, monocytes; and FIG. 3D, PMN) are shown on a logarithmic scale on the y axis for controls (-) and for
- 15 LPS before (-) and after (+) treatment with 100 mg/Kg aminoguanidine (Ag) on the x axis. Each filled in circle (●) represents the cell count from an individual rat.

- FIG. 4 is a graphical representation which shows the effect of aminoguanidine on plasma nitrate/nitrite levels in Lewis rats treated with 100  $\mu\text{g}$  LPS. Plasma
- 20 nitrate/nitrite levels in  $\mu\text{g}$  are shown on the y axis for 20 control (-) and for LPS before (-) and after (+) treatment with 100 mg/Kg aminoguanidine.

Fig. 5 is a graph demonstrating that aminoguanidine attenuates IL-1-induced  $\text{PGE}_2$  production by rat islets.

- Fig. 6 is a graph demonstrating that aminoguanidine attenuates IL-1-induced  $\text{PGE}_2$
- 25 production by purified B-cells.



Fig. 7 is a graph demonstrating that exogenous nitric oxide stimulates PGE<sub>2</sub> production by rat islets.

In order to further illustrate the invention, the following detailed Examples were carried out although it should be understood that the invention is not limited to these specific Examples or the details described therein which are for illustrative and not limitative purposes. The results obtained in these Examples are further shown in Tables 1 to 4 hereinbelow and the accompanying Figures 1 to 4.

### EXAMPLE 1

Endotoxin-induced acute uveitis and generalized vascular leakage: inhibition by aminoguanidine

#### Methods

#### Animals and materials

Male Lewis rats (~200 g) were purchased from Harlan Sprague Dawley (Indianapolis, IN) and housed and cared for in accordance with the guidelines of the Washington University Committee for the Humane Care of Laboratory Animals and in accordance with NIH guidelines on laboratory animal welfare. Rats were housed individually, fed standard rat chow (Ralston Purina, Richmond, IN) and water ad libitum, and were on a 12 hour light/dark cycle. Aminoguanidine (hemisulfate), and lipopolysaccharide (LPS; Salmonella minnesota) were purchased from Sigma (St. Louis, MO). <sup>125</sup>I and <sup>46</sup>Sc microspheres were obtained from NEN Research Products (Boston, MA). 1311 was obtained from ICN Biomedicals, Inc. (Costa Mesa, CA).

**Induction of LPS-induced vascular injury**

LPS was dissolved in steril pyrogen-free 0.9% saline at concentrations of 1 pg/pl, and unless stated otherwise, 50 pl was injected into each hind footpad (100 pg total dose per rat) using metofane anesthesia as described previously by other  
5 investigators [Herbort et al., Graefe's Arch. Clin. Exn. Ophthalmol. 226, pp. 553-558 (1988); and Hoekzema et al., Invest. Ophthalmol. Vis. Sci. 33, pp. 532-539 (1992)]. Control rats received an equal volume of 0.9% saline. 100 mg/kg body weight aminoguanidine was injected subcutaneously in 30 LPS-treated and in control rats at 0, 3, 6, 12, 18 and within 60 minutes of the initiation of the  
10 test, which corresponds to 20-24 hours after LPS injection.

**Assessment of vascular function**

Regional vascular albumin permeation was quantified by use of an isotope dilution technique based on the injection of bovine serum albumin (BSA) labeled with 2 different iodine isotopes,  $^{125}\text{I}$  and  $^{131}\text{I}$  [[Pugliese et al., Metabolism 39 pp. 690-697  
15 (1990); Pugliese et al., Diabetes 39, pp. 323-332 (1990); and Pugliese et al., Diabetes 39, pp. 312-322 (1990)].  $^{125}\text{I}$ -BSA was used to quantify vascular albumin filtration after 10 min. of tracer circulation while  $^{131}\text{I}$ -BSA served as a plasma volume marker for correction of  $^{125}\text{I}$ -BSA tissue activity for tracer contained within vessels. Purified monomer IBSA (1 mg) was iodinated with 1  
20 mCi of  $^{131}\text{I}$  or  $^{125}\text{I}$  by the iodogen, method as previously described [Pugliese et al., Diabetes 39, pp. 323-332 (1990)].

Rats were anesthetized with Inactin (Byk Gulden, Konstanz, FRG) (-100 mg/kg body weight injected i.p.), and core body temperature maintained at  $37 \pm 0.5^\circ\text{C}$  using heat lamps, a  $37^\circ\text{C}$  surgical tray, and, a rectal temperature probe. The left  
25 femoral vein, left iliac artery, and right subclavian artery were cannulated with polyethylene tubing (0.58 mm i.d.) filled with heparinized saline (400 U heparin/ml). The femoral vein cannula was used for tracer injection and the subclavian artery cannula was connected to a pressure transducer for blood pressure

m nitroging. The left iliac artery was connected to a 1 ml syringe attached to a Harvard Model 940 constant withdrawal pump preset to withdraw at a constant rate of, 0.055 ml/min. The trachea was intubated and connected to a small rodent respirator for continuous ventilatory support. Microspheres were  
5 injected into the left ventricle through a carotid-artery cannula.

At time 0,  $^{125}\text{I}$ -albumin was injected and the withdrawal pump was started simultaneously. Eight min. after time 0,  $^{131}\text{I}$ -BSA was injected, followed by the microspheres. At the 10 min mark, the heart was excised to stop all blood flow, the withdrawal pump was stopped simultaneously, and various tissues were  
10 sampled for gamma spectrometry.

The left eye was dissected as previously-described [Pugliese et al., Diabetes 39, pp. 323-332 (1990); and Pugliese et al., Diabetes 39, pp. 312-322 (1990)] and all tissue samples and arterial plasma samples were weighed, then counted in a gamma spectrometer. A quantitative index of  $^{125}\text{I}$ -BSA tissue clearance was calculated as  
15 previously described in [Pugliese et al., Metabolism 39, pp. 690-697 (1990); Pugliese et al., Diabetes 39, pp. 323-332 (1990); Pugliese et al., and Diabetes 39, pp. 312-322 (1990)] and expressed as  $\mu\text{g}$  plasma/g tissue wet weight/min. Briefly,  $^{125}\text{I}$ -BSA tissue activity was corrected for tracer contained within the tissue vasculature by multiplying  $^{125}\text{I}$ -BSA activity in the tissue by the  
20 ratio of  $^{125}\text{I}$ -BSA/ $^{131}\text{I}$ -BSA activities in the arterial plasma sample obtained at the end of the test. The vascular-corrected  $^{125}\text{I}$ -BSA tissue activity was divided by the time-averaged  $^{125}\text{I}$ -BSA plasma activity (obtained from a well mixed sample of plasma taken from the withdrawal syringe) and by the tracer circulation time (10 min) and then normalized per g tissue wet weight. To calculate blood flow, total  
25 activity of  $^{46}\text{Sc}$  in each ocular tissue was divided by the activity of  $^{46}\text{Sc}$  in the reference blood sample obtained from the withdrawal pump syringe, multiplied by the pump withdrawal rate, and expressed as ml/g tissue/min [Pugliese et al. Diabetes 39, pp. 323-332 (1990) and Pugliese et al., Diabetes 39, pp. 312-322 (1990)]. Other non-ocular tissues (aorta, kidney, skin, skeletal muscle, sciatic

nerv ) also were sampled to assess if LPS induced a generalized vascular dysfunction.

#### Assessment of cells in aqueous humor

Aqueous fluid was collected from the left eye only (the right carotid artery was  
5 ligated for the blood flow studies and this eye was not used for function studies)  
using a 100 µg heparinized capillary tube and placed in a microfuge tube. Well  
mixed aliquots (2 µl) were spread on a siliconized glass slide, air dried, stained  
with Wright's stain, and the total number of cells and a differential cell count were  
performed using a Leitz orthoplan light microscope.

#### 10 Plasma nitrate/nitrite measurements

Anticoagulated (heparin) plasma samples were centrifuged at 7500 rpm for 1 hour  
at 4°C using a 10,000 5 molecular weight cut off Centricon filter (Amicon,  
Beverly, MA). Plasma nitrate was enzymatically reduced to nitrite using  
Aspergillus niger nitrate reductase (Sigma, St. Louis, MO). Briefly, the sample  
15 was incubated with 40 µM NADPH and 14 mU of enzyme in a final volume of 50  
41 of 20 mM Tris, pH 7.6; the reaction was terminated after 5 minutes at 20°C by  
dilution with 50 µl of water followed by addition of 10 µl of freshly prepared  
DAN reagent (0.05 mg/ml in 0.6 M HCl) for determination of nitrite. The DAN  
assay is a modification of the conventional method of Damiani and Burini for the  
20 fluorometric determination of nitrite [Talanta 33, 649-652 (1986)].  
2,3-Diaminonaphthalene (DAN) is reacted with nitrite under acidic conditions to  
form 1-(H)-naphthotriazole, a fluorescent product. After a 10 minute incubation  
at 20°C, the reaction was terminated with 5 µl of 2.8 N NaOH, which maximizes  
the intensity of the fluorescent signal. Formation of the  
25 2,3-diaminonaphthotriazole was measured using a Pandex (IDEXX Laboratories,  
Inc., Westbrook, ME) fluorescent plate reader with excitation at 365 nm and  
emission read at 450 nm with a gain setting at 100%. Plasma nitrite levels were  
calculated by first subtracting the value of the enzyme blank (nitrate reductase plus  
NADPH) from the experimental reading, then calculating the value using a

standard curve for nitrite to which NADPH was added.

### **Statistical analysis**

All results are expressed as means  $\pm$  standard deviations. Overall differences among test groups for each parameter were first assessed by the Van der Waerden test, and individual pair-wise group comparisons were evaluated by at least square means analysis only if the Van der Waerden test was significant at  $p < 0.05$  for a given parameter. A nonparametric Blom transformation of all data was performed prior to assessment of individual pair-wise group differences.

## **10 Results**

### **Generalized vascular leakage of $^{125}\text{I}$ -albumin**

In preliminary tests, 50, 100, and 200  $\mu\text{g}$  LPS were injected either as a single injection into one hind footpad or as a divided dose injected into both hind footpads of Lewis rats. In general, increases in  $^{125}\text{I}$  albumin leakage were greater for the divided dose of LPS versus a single injection. Figure 1 shows changes in  $^{125}\text{I}$ -albumin leakage expressed as a fold increase over control values for LPS given as a divided dose. Except for sciatic nerve, maximal increases in  $^{125}\text{I}$ -albumin leakage normalized to control values were observed with 100  $\mu\text{g}$  LPS and this dose was selected for subsequent tests.

Table 1 shows changes in  $^{125}\text{I}$ -albumin permeation resulting from the injection of 100  $\mu\text{g}$  LPS (50  $\mu\text{g}$ /footpad) into footpads of Lewis rats. The Van der Waerden test indicated highly significant group differences for  $^{125}\text{I}$ -albumin leakage in the retina, anterior uvea, choroid/sclera, and aqueous fluid ( $p < 0.0001$ ), while changes were absent in brain. At the dose and frequency used, aminoguanidine attenuated the  $^{125}\text{I}$  LPS-induced  $^{125}\text{I}$ -albumin leakage by -75% in the retina, sciatic nerve, and aorta, by -50% in the aqueous fluid and anterior uvea, and by -30% in the posterior uvea, without affecting  $^{125}\text{I}$ -albumin leakage in controls.

Figure 2 shows changes in regional blood flows expressed as a fold increase over control values for LPS administered as a divided dose. Regional blood flows

increased with increasing dose of LPS in the anterior and posterior uveal vasculatures and in the heart, plateaued in the retinal and sciatic nerve at 100 pg LPS, and was unaffected by LPS in the kidney when measured 20 hours after LPS injection. The Van der Waerden test indicated significant group differences for blood flow in the anterior uvea and choroid/sclera but not in the retina, sciatic nerve, brain, heart, and kidney (Table 2). LPS increased blood flow ~40% in the anterior uvea and ~25% in the choroid-sclera and these increases were prevented by aminoguanidine.

#### Gravimetric and hemodynamic parameters

All gravimetric and hemodynamic parameters, including body weight, mean arterial blood pressure, cardiac output, cardiac index, total peripheral resistance, GFR (normalized either to whole kidney or g kidney wet weight), glomerular filtration fraction, and renal vascular resistance, were unaffected by the injection of 100 µg LPS (Table 3).

#### Aqueous fluid leukocyte cell counts

Number of cells in a well mixed 2 µl sample of aqueous fluid from controls was low, ranging from no cells in 6 animals to ~25 cells in 2 rats (Figure 3); the median value was ~5 cells/2 µl fluid and was unaffected by aminoguanidine treatment in controls. As shown in Figure 3A, 100 µl LPS significantly increased the number of cells in 2 µl of aqueous fluid. Figure 3 also shows the types of infiltrating cells into the aqueous fluid following LPS injection. Virtually all cells in the aqueous fluid of controls (± aminoguanidine) were lymphocytes. In aqueous fluid of rats treated with 100 µg LPS, lymphocytes (Figure 3B), monocytes (Figure 3C), and PMNs (Figure 3D) increased significantly with the largest increase observed for PMNs. Aminoguanidine reduced the total number of

cells in the aqueous fluid of LPS-treated rats, including ~90% reduction in the number of PMNs.

#### **Plasma nitrate/nitrite measurement**

5 Plasma nitrate/nitrite levels were  $17.9 \pm 8.6 \mu\text{M}$  for controls and were increased ~65% in LPS-treated rats (Figure 4). Aminoguanidine treatment prevented the LPS-induced increases in plasma nitrate/nitrite levels.

10 It is seen from the above results that aminoguanidine markedly attenuated manifestations of endotoxin-induced acute uveitis (vascular-leakage, increased blood flow, and exudation of leukocytes into the aqueous fluid) as well as elevated plasma nitrate/nitrite levels. Aminoguanidine also significantly attenuated or completely prevented systemic effects of endotoxin on vascular leakage, i.e., edema (an important manifestation/consequence of inflammation) in nerve, aorta, and small intestine.

Table 1: Effects of LPS (100 µg) and aminoguanidine (100 mg/kg) on regional <sup>125</sup>I-albumin permeation (µg plasma/min/g wet weight)

		control	LPS	LPS + aminoguanidine
	number of rats	14	19	11
5	eye			
	aqueous fluid	65 ± 23 <sup>a</sup>	294 ± 81 <sup>b</sup>	204 ± 53 <sup>b,f</sup>
	anterior uvea	270 ± 53	611 ± 110 <sup>b</sup>	423 ± 67 <sup>b,c</sup>
	posterior uvea	258 ± 75	612 ± 110 <sup>b</sup>	497 ± 96 <sup>b,f</sup>
	retina	66 ± 14	154 ± 32 <sup>b</sup>	86 ± 23 <sup>c</sup>
	sciatic nerve	62 ± 14	167 ± 35 <sup>b</sup>	91 ± 20 <sup>c,e</sup>
10	aorta	75 ± 26	245 ± 64 <sup>b</sup>	114 ± 43 <sup>d,e</sup>
	skeletal muscle	44 ± 17	62 ± 11	51 ± 10
	skin	110 ± 27	209 ± 73 <sup>b</sup>	186 ± 49 <sup>c</sup>
	brain	23 ± 11	24 ± 11	25 ± 15
	heart	621 ± 57	585 ± 116	624 ± 86
15	small intestine	377 ± 112	567 ± 247 <sup>d</sup>	375 ± 100 <sup>e</sup>
	kidney	612 ± 212	1,173 ± 407 <sup>b</sup>	1,578 ± 251 <sup>b,f</sup>

Male Lewis rats were treated with 100 µg LPS (50 µg in each hind footpad) ± 100 mg/kg body weight aminoguanidine hemisulfate (at the time of injection of LPS and 3, 6, 12, 18, and 20–24 hours thereafter). LPS was injected at noon and the animals were sacrificed the following morning.

<sup>a</sup> values are mean ± SD

Significantly different from controls by least square means analysis:

<sup>b</sup> p<0.0001; <sup>c</sup> p<0.001; <sup>d</sup> p<0.05

Significantly different from LPS-treated rats least square means analysis:

25 <sup>e</sup> p<0.0001; <sup>f</sup> p<0.005; <sup>g</sup> p<0.05



Table 2: Effects of LPS (100  $\mu$ g) and aminoguanidine (100 mg/kg) on regional blood flows (ml/min/g wet weight)

	control	LPS	LPS + aminoguanidine
number of rats	11	13	9
5 eye			
anterior uvea	1.8 $\pm$ 0.4	2.5 $\pm$ 0.6 <sup>b</sup>	1.9 $\pm$ 0.3 <sup>d</sup>
posterior uvea	3.4 $\pm$ 0.6	4.3 $\pm$ 0.9 <sup>c</sup>	3.7 $\pm$ 0.4
retina	0.42 $\pm$ 0.03	0.45 $\pm$ 0.07	0.42 $\pm$ 0.04
sciatic nerve	0.07 $\pm$ 0.01	0.08 $\pm$ 0.03	0.08 $\pm$ 0.03
brain	0.6 $\pm$ 0.1	0.6 $\pm$ 0.1	0.6 $\pm$ 0.1
10 heart	4.9 $\pm$ 1.4	6.1 $\pm$ 1.2	5.4 $\pm$ 1.7
kidney	4.8 $\pm$ 0.9	4.7 $\pm$ 0.6	4.9 $\pm$ 0.6

Male Lewis rats were treated with 100  $\mu$ g LPS (50  $\mu$ g in each hind footpad)  $\pm$  100 mg/kg body weight aminoguanidine hemisulfate (at the time of injection of LPS and 3, 6, 12, 18, and 20–24 hours thereafter). LPS was injected at noon and the animals were sacrificed the following morning.

<sup>a</sup> values are mean  $\pm$  SD

Significantly different from controls by least square means analysis:

<sup>b</sup>  $p < 0.0001$ ; <sup>c</sup>  $p < 0.005$

Significantly different from LPS-treated rats least square means analysis:

<sup>d</sup>  $p < 0.005$

Table 3: Effects of LPS (100 µg) and aminoguanidine (100 mg/kg) on gravimetric and hemodynamic parameters

		control	LPS	LPS + aminoguanidine
	number of rats	5	6	7
	body weight (g)	237 ± 15 <sup>a</sup>	225 ± 9	229 ± 12
5	mean arterial blood pressure (mm Hg)	120 ± 9	121 ± 9	124 ± 10
	cardiac output (ml/min)	81 ± 9	75 ± 4	77 ± 3
10	cardiac index (ml/min/100 g b.w.)	343 ± 19	334 ± 13	336 ± 23
	total peripheral resistance (mm Hg/ml/min)	1.42 ± 0.10	1.55 ± 0.14	1.54 ± 0.11
	GFR (ml/min/whole kidney)	0.96 ± 0.07	0.97 ± 0.06	0.95 ± 0.14
15	GFR (ml/min/g kidney)	0.87 ± 0.07	0.90 ± 0.11	0.87 ± 0.15
	filtration fraction (GFR/renal blood flow)	0.34 ± 0.08	0.34 ± 0.05	0.31 ± 0.06
20	renal vascular resistance (mm Hg/ml/min)	0.97 ± 0.07	0.97 ± 0.06	0.95 ± 0.14

Male Lewis rats were treated with 100 µg LPS (50 µg in each hind footpad) ± 100 mg/kg body weight aminoguanidine hemisulfate (at the time of injection of LPS and 3, 6, 12, 18, and 20–24 hours thereafter). LPS was injected at noon and the animals were sacrificed the following morning.

25 <sup>a</sup> values are mean ± SD

**EXAMPLE 2**

End toxin-induced acute uveitis and generalized vascular leakage: inhibition by methylguanidine

**Methods****5 Animals and Materials**

Male Lewis rats (~200 g) were purchased from Harlan Sprague Dawley (Indianapolis, IN) and housed and cared for in accordance with the guidelines of the University Committee for the Humane Care of Laboratory Animals in accordance with NIH guidelines on laboratory animal welfare. Rats were housed  
10 individually, fed standard rat chow (Ralston Purina, Richmond, IN) and water ad libitum, and were on a 12 hour light/dark cycle. Methylguanidine (hydrochloride) and lipopolysaccharide (LPS; Salmonella minnesota) were purchased from Sigma (St. Louis, MO). <sup>125</sup>I was obtained from NEN Research Products (Boston, MA). <sup>131</sup>I was obtained from ICN Biomedicals, Inc. (Costa Mesa, CA).

**15 Induction of LPS-Induced Vascular Injury**

LPS was dissolved in sterile pyrogen-free 0.9% saline at concentrations of 1 µg/µl, and 50 µl was injected into each hind footpad (100 µg total dose per rat) using metofane anesthesia as described previously by other investigators [Herbert et al., Graefe's Arch. Clin. Exp. Ophthalmol. 226, pp. 553-558 (1988); and  
20 Hoekzema et al., Invest. Ophthalmol. Vis. Sci. 33, pp. 532-539 (1992)]. Control rats received an equal volume of 0.9% saline. 50 mg/kg body weight methylguanidine was injected subcutaneously in LPS-treated and in control rats at 0, 3, 6, 12, 18 and 20-24 hours after LPS injection. Animals were killed for the vascular function studies 20 to 24 hours after LPS injection.

**25 Assessment of Vascular Function**

Regional vascular albumin permeation was quantified by use of an isotope dilution technique based on the injection of bovine serum albumin (BSA) labeled with 2 different iodine isotopes, <sup>125</sup>I and <sup>131</sup>I [Pugliese et al., Metabolism 39, pp. 690-697

(1990); Pugliese et al., Diabetes 39, pp. 323-332 (1990); and Pugliese et al., Diabetes 39, pp. 312-322 (1990)].  $^{125}\text{I}$ -BSA was used to quantify vascular albumin filtration after 10 minutes of tracer circulation, while  $^{131}\text{I}$ -BSA served as a plasma volume marker for correction of  $^{125}\text{I}$ -BSA tissue activity for tracer

- 5 contained within vessels. Purified monomer BSA (1 mg) was iodinated with 1 mCi of  $^{131}\text{I}$  or  $^{125}\text{I}$  by the iodogen method as previously described in Pugliese et al., Diabetes 39, pp. 323-332 (1990).

Rats were anesthetized with Inactin (Byk Gulden Konstanz, FRG) (~100 mg/kg body weight injected i.p.), and core body temperature maintained at  $37 \pm 0.5^\circ\text{C}$   
10 using heat lamps, a  $37^\circ\text{C}$  surgical tray, and a rectal temperature probe. The left femoral vein, left iliac artery, and right subclavian artery were cannulated with polyethylene tubing (0.58 mm i.d.) filled with heparinized saline (400 U heparin/ml). The femoral vein cannula were used for tracer injection and the subclavian artery cannula was connected to a pressure transducer for blood pressure  
15 monitoring. The left iliac artery was connected to a 1 ml syringe attached to a Harvard Model 940 constant withdrawal pump preset to withdraw at a constant rate of 0.055 ml/min. The trachea was intubated and connected to a small rodent respirator for continuous ventilatory support.

At time 0,  $^{125}\text{I}$ -albumin was injected i.v. and the withdrawal pump was started  
20 simultaneously. Eight minutes after time 0,  $^{131}\text{I}$ -BSA was injected. At the 10 minute mark, the heart was excised to stop all blood flow, the withdrawal pump was stopped simultaneously, and various tissues were sampled for gamma spectrometry. The left eye was dissected as previously described [Pugliese et al., Diabetes 39, pp. 323-332 (1990) and Pugliese et al., Diabetes 39, pp. 312-322  
25 (1990)] and all tissue samples and arterial plasma samples were weighed, then counted in a gamma spectrometer. A quantitative index of  $^{125}\text{I}$ -BSA tissue clearance was calculated as previously described [Pugliese et al., Metabolism 39, pp. 690-697 (1990); Pugliese et al., Diabetes 39, pp. 323-332 (1990); and Pugliese et al., Diabetes 39, pp. 312-322 (1990)] and expressed as  $\mu\text{g plasma/g}$

tissue wet weight/min. Briefly,  $^{125}\text{I}$ -BSA tissue activity was corrected for tracer contained within the tissue vasculature by multiplying  $^{125}\text{I}$ -BSA activity in the tissue by the ratio of  $^{125}\text{I}$ -BSA/131I-BSA activities in the arterial plasma sample obtained at the end of the test. The vascular corrected  $^{125}\text{I}$ -BSA tissue activity was  
5 divided by the time-averaged  $^{125}\text{I}$ -BSA plasma activity (obtained from a well-mixed sample of plasma taken from the withdrawal syringe) and by the tracer circulation time (10 minutes) and then normalized per g tissue wet weight. Other non-ocular tissues (aorta, kidney, skin, skeletal muscle, sciatic nerve) also were sampled to assess if LPS induced a generalized vascular dysfunction.

#### 10 Statistical Analysis

All results are expressed as means  $\pm$  standard deviations. Overall differences among test groups for each parameter were assessed by Students' test.

#### Generalized Vascular Leakage of $^{125}\text{I}$ -Albumin

Table 4 shows changes in  $^{125}\text{I}$ -albumin permeation resulting from the injection of  
15 100  $\mu\text{g}$  LPS (50  $\mu\text{g}$ /footpad) into footpads of Lewis rats. Highly significant group differences for  $^{125}\text{I}$ -albumin leakage were evident in the aqueous fluid, anterior uvea, choroid/sclera, retina, sciatic nerve, aorta, and kidney ( $p < 0.0001$ ), while smaller increases were observed in the skin and skeletal muscle. No LPS-induced changes were present in brain, heart, or small intestine. At the dose and frequency  
20 used, methylguanidine attenuated the LPS-induced  $^{125}\text{I}$ -albumin leakage in aqueous fluid, anterior uvea, and kidney and prevented the LPS-induced increases in albumin leakage in the choroid/sclera, retina, sciatic nerve, aorta, and skin.

It is seen from the above results that methylguanidine (at approximately one-half of the dose of aminoguanidine used in Example 1) was as effective as (or more  
25 effective than) aminoguanidine in preventing endotoxin-induced vascular leakage (an important manifestation/consequence of inflammation) in uveal tissue as well as in the sciatic nerve, aorta, skeletal muscle, skin, and kidney.

Similar results as obtained in Examples 1 and 2 can be obtained by substituting N,N'-diaminoguanidine or 1,1-dimethylguanidine for equivalent amounts of aminoguanidine or methylguanidine, respectively, in said Examples.

Table 4: Effects of LPS ( $\mu$ g) and methylguanidine (mg) on regional

5  $^{125}$ I-albumin permeation<sup>a</sup>

	control	LPS	LPS + aminoguanidine
number of rats	5	8	4
aqueous	154 $\pm$ 100	495 $\pm$ 283 <sup>a</sup>	335 $\pm$ 30 <sup>c</sup>
anterior uvea	266 $\pm$ 52	618 $\pm$ 106 <sup>a</sup>	383 $\pm$ 32 <sup>c,c</sup>
choroid/sclera	298 $\pm$ 67	582 $\pm$ 77 <sup>a</sup>	357 $\pm$ 50 <sup>d</sup>
10 retina	68 $\pm$ 15	168 $\pm$ 28 <sup>a</sup>	67 $\pm$ 7 <sup>d</sup>
sciatic nerve	71 $\pm$ 14	187 $\pm$ 32 <sup>a</sup>	69 $\pm$ 3 <sup>d</sup>
aorta	75 $\pm$ 24	211 $\pm$ 43 <sup>a</sup>	102 $\pm$ 8 <sup>d</sup>
skeletal muscle	54 $\pm$ 19	103 $\pm$ 46 <sup>c</sup>	63 $\pm$ 11
skin	99 $\pm$ 29	224 $\pm$ 65 <sup>b</sup>	106 $\pm$ 16 <sup>f</sup>
15 brain	20 $\pm$ 4	25 $\pm$ 6	19 $\pm$ 5
heart	623 $\pm$ 43	699 $\pm$ 58	629 $\pm$ 82
small intestine	414 $\pm$ 40	559 $\pm$ 147	423 $\pm$ 188
kidney	635 $\pm$ 239	1,561 $\pm$ 221 <sup>a</sup>	1,042 $\pm$ 253 <sup>c,c</sup>

<sup>a</sup>  $\mu$ g plasma/g wet weight/min; values are mean  $\pm$  SD.

20 Male, Lewis rats were treated with 100  $\mu$ g LPS (50  $\mu$ g in each hind footpad)  $\pm$  50 mg/kg body weight methylguanidine hydrochloride (at the time of injection of LPS and 3, 6, 12, 18, and 20-24 hours thereafter). LPS was injected at noon and the animals were sacrificed the following morning.

Significantly different from untreated controls:

25 <sup>a</sup>  $p < 0.0001$ ; <sup>b</sup>  $p < 0.005$ ; <sup>c</sup>  $p < 0.05$

Significantly different from LPS:

<sup>d</sup>  $p < 0.001$ ; <sup>e</sup>  $p < 0.005$ ; <sup>f</sup>  $p < 0.01$

Inflammation conditions are characterized by the accumulation of polymorphonuclear leukocytes, macrophages and monocytes at the site of injury. Macrophage and monocytes have been shown to produce high levels of inflammatory mediators at the sites of inflammation. In the carrageenin and carrageenin induced paw oedema models of inflammation the production of nitric oxide has also been demonstrated [Ialenti et al. European J. of Pharmacol. 211:177-182 (1991)]. Macrophage are believed to be the cellular source of inducible nitric oxide synthase (iNOS) and the cell type that produces nitric oxide at the site of inflammation. Macrophage release of cytokines during the inflammatory reaction may also induce the expression of iNOS by other cellular sources. Proinflammatory prostaglandin (PGs) and thromboxane production has also been demonstrated in these animal models of inflammation [Masferrer et al., Proc. Natl. Acad. Sci. USA 91:3228-3232 (1994)]. The cellular source being macrophage and monocytes and fibroblasts. Cyclooxygenase (COX) catalyzes the first enzymatic reaction in the production of prostaglandins, prostacyclin, and thromboxane. Two isoforms of COX have been demonstrated. Constitutive COX (COX-1) is found in most tissues and is responsible for the physiological production of prostaglandins (Dewitt, Biochim. Biophys. Acta 3:121-124 (1991)]. Prostaglandins, produced by COX-1, play a prominent role in the normal physiological function of the stomach and kidney [Dewitt, *supra*]. Expression of other isoforms of COX is inducible by cytokines. This isoform, inducible COX (or COX-2) is believed to be responsible for the production of PGs under conditions of inflammation and injury [Fletcher et al., J. Biol. Chem. 267:4338-4344 (1992)]. Recent studies have shown the expression of COX-2 at the level of mRNA, protein, and enzymatic activity in the rat air pouch model of inflammation [Masferrer et al., *supra*]. During this inflammation the production of PGs appears to be entirely the result of COX-2 activity [Masferrer et al., *supra*].

Autoimmune diabetes is an inflammatory disease that is characterized by macrophage and lymphocyte invasion of islets, followed by  $\beta$ -cell death [Bach, Endocrine Rev. 15:516-542 (1994)]. Cytokines released during this lymphocytic

infiltration have been proposed to participate in  $\beta$ -cell destruction during the development of autoimmune diabetes [Corbett et al., Diabetes 41:897-903 (1992)]. Treatment of rat islets with the cytokine IL-1, induces a potent inhibition of insulin secretion that is followed by  $\beta$ -cell destruction. Nitric oxide appears to

5 mediate the inhibitory and destructive effects of IL-1 on islets. Inhibitors of nitric oxide synthase (aminoguanidine and monomethyl-L-arginine) completely prevent IL-1 induced inhibition of insulin secretion and islet destruction [Corbett et al., Autoimmunity 15:145-153 (1993); Corbett et al., Diabetes 41:552-556 (1991)]. IL-1 also induces the expression of COX-2 and the production of PGE<sub>2</sub> by islets

10 [Corbett et al., Biochemistry 32, 13767-13770 (1993)]. PGE<sub>2</sub> production by islets is attenuated by the nitric oxide synthase inhibitors NMMA, and aminoguanidine (AG) [Corbett et al., *supra*]. These findings suggest that cytokines, nitric oxide, and nitric oxide stimulated PGs production play key roles in the development of autoimmune diabetes, in a manner similar to inflammatory conditions where the

15 production of nitric oxide, the release of cytokines, and PGs release have been demonstrated.

### EXAMPLE 3

Additional experimental data were developed that relate to the effect of aminoguanidine on prostaglandin production as measured by cyclooxygenase-2

20 (COX-2) activity. COX-2 has been identified as a primary producer of prostaglandins during inflammation.

The data is set forth in Figs. 5-7 and is described briefly below. This data demonstrates the interactions of the nitric oxide and prostaglandin pathways. Nitric oxide appears to directly activate the enzymatic activity of COX-2 resulting in the

25 overproduction of PGE<sub>2</sub>. Inhibitors of nitric oxide synthase (AG, and NMMA) attenuate nitric oxide stimulated production of PGE<sub>2</sub>. These inhibitors do not have inhibitory effects on the expression of either iNOS or COX-2(9). Exogenous production of nitric oxide (spontaneously released by nitric oxide donor compound,



SIN-1) stimulates the production of PGE<sub>2</sub> by islets, further supporting the direct activation of COX by nitric oxide (Fig. 7). These studies support the use of iNOS inhibitors, NMMA and AG for the inhibition of PGs production under inflammatory conditions such as acute and chronic inflammation, arthritis, inflammatory bowel disease, injury, etc. The inhibitors function by preventing nitric oxide activation of COX-2.

Referring now to Fig. 5, isolated rat islets were incubated for 24 h with 5 units/ml IL-1, or 0.5 mM AG as indicated. The supernatant was removed and PGE<sub>2</sub> and nitrite formation were determined. Results demonstrate that AG attenuates IL-1-induced PGE<sub>2</sub> and completely prevents IL-1-induced nitrite formation by rat islets. These findings indicate that IL-1-induces COX-2 and iNOS expression and that nitric oxide directly activates COX-2.

In a further experiment the results of which are set forth in Fig. 6, purified  $\beta$ -cells were incubated for 24 h with 5 units/ml IL-1, 0.5 mM aminoguanidine, or 1  $\mu$ M Actinomycin D as indicated. The supernatant was removed and PGE<sub>2</sub> and nitrite formation were determined. These results further demonstrate that aminoguanidine attenuates IL-1-induced PGE<sub>2</sub> production, and completely prevents IL-1-induced nitrite formation by  $\beta$ -cells. The transcriptional inhibitor actinomycin D completely prevents PGE<sub>2</sub> and nitrite formation by  $\beta$ -cells, indicated the requirement for mRNA transcription. These findings indicate that IL-1-induces COX-2 and iNOS expression and that nitric oxide directly activates COX-2.

As further corroboration of the activity and interaction of nitric oxide in COX and PGE<sub>2</sub> production, rat islets were pretreated with 5 units/ml IL-1 or IL-1 and actinomycin D (1 $\mu$ M) for 18 h. The islets were washed and then cultured for 2 h with 30  $\mu$ M arachidonic acid (COX substrate) in the presence or absence of SIN-1 (1 mM; nitric oxide donor compound) and hemoglobin (Hb; scavenger of nitric oxide) as indicated. The results are presented in Fig. 7 and demonstrate that nitric oxide, released spontaneous by SIN-1, stimulates the activity of both constitutive

COX (COX-1; control and IL-1+Act D treatment) and inducible COX (COX-2; IL-1 treated group). Hemoglobin attenuates SIN-1 stimulated PGE<sub>2</sub> formation indicating that the effects of SIN-1 on COX activity is mediated by nitric oxide.

#### **EXAMPLE 4**

- 5    **Inhibition by aminoguanidine of the vascular injury in inflammatory bowel disease was evaluated in the rat.**

Inflammatory bowel disease was induced by feeding male Sprague-Dawley rats pulverized normal rat chow containing 5% dextran sodium sulfate (DSS), mol wt -40 - 50,000. This model is reported to induce loose stools/diarrhea in all animals  
10    within 14 days which is followed by extensive ulceration of the colon and eventually by development of carcinomas of the colon (65% of animals by 134 days) [Hirono et al., J. Natl. Cancer Inst. 66, 579-583 (1981)]. Thus the model reproduces many of the characteristic features of chronic ulcerative colitis in humans, including the development of cancer.

#### **15    Methods**

##### **Animals and materials**

Male Lewis rats (-200 g) were purchased from Harlan Sprague Dawley (Indianapolis, IN) and housed and cared for in accordance with the guidelines of the Washington University Committee for the Humane Care of Laboratory Animals  
20    and in accordance with NIH guidelines on laboratory animal welfare. Rats were housed individually, fed standard rat chow (Ralston Purina, Richmond, IN) and were on a 12 hour light/dark cycle. Aminoguanidine (hemisulfate) was purchased from Sigma (St. Louis, MO). <sup>125</sup>I and <sup>46</sup>Sc microspheres were obtained from NEN Research Products (Boston, MA).

#### **25    Induction of Inflammatory-Bowel-Disease vascular injury**

Based on pilot studies, 4 groups of rats were prepared as follows:

1. Control rats fed normal rat chow (n=9),
2. Rats fed chow containing 5% DSS (n=8),

3. Rats fed chow with 5% DSS + aminoguanidine hemisulfate added to the drinking water in a concentration to provide a daily dose of 25 mg/kg body weight/day (n=5), and
4. Rats fed chow with 5 DSS% and given 25 mg aminoguanidine hemisulfate/kg body weight/day by subcutaneous injection (n=4).

After 7 days on the DSS supplemented diet, the rats were anesthetized for assessment of vascular permeability in the cecum and large bowel. Vascular permeability was quantified by injection of radiolabeled albumin as described below.

#### 10 Assessment of vascular function

- Regional vascular albumin permeation was quantified by use of an isotope dilution technique based on the injection of bovine serum albumin (BSA) labeled with 2 different iodine isotopes,  $^{125}\text{I}$  and  $^{131}\text{I}$  [[Pugliese et al., Metabolism 39 pp. 690-697 (1990); Pugliese et al., Diabetes 39, pp. 323-332 (1990); and Pugliese et al., Diabetes 39, pp. 312-322 (1990)].  $^{125}\text{I}$ -BSA was used to quantify vascular albumin filtration after 10 min. of tracer circulation while  $^{131}\text{I}$ -BSA served as a plasma volume marker for correction of  $^{125}\text{I}$ -BSA tissue activity for tracer contained within vessels. Purified monomer IBSA (1 mg) was iodinated with 1 mCi of  $^{131}\text{I}$  or  $^{125}\text{I}$  by the iodogen, method as previously described [Pugliese et al., Diabetes 39, pp. 323-332 (1990)].

- Rats were anesthetized with Inactin (Byk Gulden, Konstanz, FRG) (-100 mg/kg body weight injected i.p.), and core body temperature maintained at  $37 \pm 0.5^\circ\text{C}$  using heat lamps, a  $37^\circ\text{C}$  surgical tray, and, a rectal temperature probe. The left femoral vein, left iliac artery, and right subclavian artery were cannulated with polyethylene tubing (0.58 mm i.d.) filled with heparinized saline (400 U heparin/ml). The femoral vein cannula was used for tracer injection and the subclavian artery cannula was connected to a pressure transducer for blood pressure

monitoring. The left iliac artery was connected to a 1 ml syringe attached to a Harvard Model 940 constant withdrawal pump preset to withdraw at a constant rate of, 0.055 ml/min. The trachea was intubated and connected to a small rodent respirator for continuous ventilatory support.

- 5 At time 0,  $^{125}\text{I}$ -albumin was injected and the withdrawal pump was started simultaneously. Eight min. after time 0,  $^{131}\text{I}$ -BSA was injected, followed by the microspheres. At the 10 min mark, the heart was excised to stop all blood flow, the withdrawal pump was stopped simultaneously, and various tissues were sampled for gamma spectrometry.
- 10 All tissue samples and arterial plasma samples were weighed and then counted in a gamma spectrometer. A quantitative index of  $^{125}\text{I}$ -BSA tissue clearance was calculated as previously described in [Pugliese et al., *Metabolism* 39, pp. 690-697 (1990); Pugliese et al., *Diabetes* 39, pp. 323-332 (1990); Pugliese et al., and *Diabetes* 39, pp. 312-322 (1990)] and expressed as  $\mu\text{g plasma/g tissue wet}$
- 15  $\text{weight/min}$ . Briefly,  $^{125}\text{I}$ -BSA tissue activity was corrected for tracer contained within the tissue vasculature by multiplying  $^{125}\text{I}$ -BSA activity in the tissue by the ratio of  $^{125}\text{I}$ -BSA/ $^{131}\text{I}$ -BSA activities in the arterial plasma sample obtained at the end of the test. The vascular-corrected  $^{125}\text{I}$ -BSA tissue activity was divided by the time-averaged  $^{125}\text{I}$ -BSA plasma activity (obtained from a well mixed sample of
- 20 plasma taken from the withdrawal syringe) and by the tracer circulation time (10 min) and then normalized per g tissue wet weight.

### Results

- The vascular permeability changes induced by 5% DSS and the effects of aminoguanidine on them are summarized in Table 5. Vascular leakage was
- 25 increased approximately 2 fold by 5% DSS in the cecum and in all portions of the colon. These increases were markedly attenuated in the cecum, proximal colon, and mid-colon by oral or subcutaneous aminoguanidine. The effects of

amin guanidine on vascular leakage of albumin in the distal colon were less impressive, although in animals given aminoguanidine by injection, leakage was substantially reduced ( $p=0.065$ ). The reason oral aminoguanidine was less effective on permeability changes in the distal colon may be due to absorption of the drug in the proximal segments of bowel with insufficient amounts remaining to impact on leakage in the distal colon.

These results show that aminoguanidine given orally or by subcutaneous injection is efficacious in attenuating vascular damage in an animal model of inflammatory bowel disease. Since increased vascular leakage is a characteristic feature of acute and chronic inflammation and contributes to the diarrhea associated with the disease, these findings support the claim that aminoguanidine may be useful in the treatment of inflammatory bowel disease in human subjects.

TABLE 5: Effects of aminoguanidine<sup>a</sup> on vascular leakage into large bowel in rats given 5% DSS<sup>b</sup> in the diet for 7 days

	Cecum	Proximal colon	Mid-colon	Distal colon
Control (n=9)	218 $\pm$ 45 <sup>c</sup>	220 $\pm$ 47	247 $\pm$ 64	264 $\pm$ 35
5% DSS (n=8)	458 $\pm$ 68 <sup>d</sup>	501 $\pm$ 107 <sup>d</sup>	464 $\pm$ 98 <sup>d</sup>	562 $\pm$ 198 <sup>d</sup>
+Ag Oral (n=5)	281 $\pm$ 89 <sup>e</sup>	249 $\pm$ 94 <sup>e</sup>	269 $\pm$ 78 <sup>e</sup>	523 $\pm$ 237
+Ag Injection (n=4)	274 $\pm$ 63 <sup>e</sup>	222 $\pm$ 87 <sup>e</sup>	209 $\pm$ 55 <sup>e</sup>	319 $\pm$ 88

<sup>a</sup> 25 mg/kg body weight per day in drinking water (oral) or by subcutaneous injection

<sup>b</sup> dextran sodium sulfate, (mol. wt. = 40,000–50,000)

<sup>c</sup> mean  $\pm$  SD of albumin permeation expressed as  $\mu$ g plasma/g wet wt/min

<sup>d</sup> significantly different from control:  $p<0.01$

<sup>e</sup> significantly different from 5% DSS:  $p<0.01$

The inhibitors of nitric oxide formation described herein can be used for administration to warm blooded mammals by conventional means, preferably in formulations with pharmaceutically acceptable diluents and carriers. The amount of the active inhibitor to be administered must be an effective amount, that is, an amount which is medically beneficial but does not present toxic effects which outweigh the advantages which accompany its use. It would be expected that the adult human daily dosage would normally range upward from about one milligram per kilo of body weight of the drug. Suitable routes of administration include, where appropriate, topical delivery via salves, ointments and solutions; or locally through suppositories, pessaries, and the like; orally in the form of capsules, tablets, syrups, elixirs and the like; and parenteral administration, e.g., intravenously, intraperitoneally or subcutaneously. Intravenous administration of the drug in aqueous solution such as physiologic saline is illustrative. Appropriate formulations of the drug in pharmaceutically acceptable diluents and carriers in therapeutic dosage form can be prepared by reference to general texts in the field such as, for example, Remington's Pharmaceutical Sciences, Ed. Arthur Osol. 16th ed., 1980, Mack Publishing Co., Easton, PA.

Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such examples be included within the scope of the appended claims.

**WHAT IS CLAIMED IS:**

- 1 1. A method of inhibiting nitric oxide production in a warm blooded mammal  
2 afflicted with the physiological conditions manifested by an acute or chronic  
3 inflammatory disease or condition which comprises administering to said mammal  
4 a nitric oxide inhibitory effective amount of an inhibitory compound selected from  
5 the group consisting of aminoguanidine, N,N'-diaminoguanidine, methylguanidine  
6 and 1,1-dimethylguanidine.
- 1 2. The method of Claim 1 in which the inhibitory compound is  
2 aminoguanidine.
- 3 3. The method of Claim 1 in which the inflammatory disease or condition is  
4 treatable by topical/local administration of said inhibitory compound.
- 1 4. The method of Claim 3 in which the inflammatory disease or condition  
2 includes but is not limited to a member selected from the group consisting of acute  
3 and chronic vaginitis; arthritis; insect bites; burns (thermal, chemical, and  
4 electrical); sunburn; acute and delayed hypersensitivity; skin conditions such as  
5 psoriasis, whether acute or chronic; eczema; contact dermatitis; poison ivy; poison  
6 oak; and poison sumac.
- 1 5. The method of Claim 1 in which the inflammatory disease or condition is  
2 treatable by oral administration of said inhibitory compound.
- 1 6. The method of Claim 5 in which the inflammatory disease or condition  
2 includes but is not limited to a member selected from the group consisting of acute  
3 and chronic gastroenteritis and colitis; arthritis; acute and chronic cystitis and  
4 urethritis; and inflammatory bowel/Crohn's disease.

1 7. The method of Claim 1 in which the inflammatory disease or condition is  
2 treatable by parenteral administration of said inhibitory compound.

1 8. The method of Claim 7 in which the inflammatory disease or condition  
2 includes but is not limited to a member selected from the group consisting of acute  
3 and chronic infections (bacterial and fungal, including diphtheria and pertussis);  
4 acute and chronic serositis (pericarditis, peritonitis, synovitis, pleuritis and  
5 tendinitis); uremic pericarditis; acute and chronic cholecystitis; meningitis;  
6 encephalitis; arthritis; graft vs. host disease; pernicious anemia; Type I diabetes  
7 mellitus; rheumatoid arthritis; multiple sclerosis; transplant rejection; inflammation  
8 due to toxic shock or trauma; adult respiratory distress syndrome; reperfusion  
9 injury; and inflammatory bowel/Crohn's disease.



**ANY REFERENCE TO DRAWINGS  
IN THE SPECIFICATION IS  
TO BE CONSIDERED NON-EXISTENT  
(ART. 14(2))**

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/13788

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/155

US CL :514/634

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/634

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,317,040 (GOLDMAN) 31 May 1994, see the Abstract and column 5, line 5 through column 6, line 21.	1-3, 5, 7, 8
X	US, A, 4,758,583 (CERAMI et al.) 19 July 1988, see column 5, line 44, column 6, lines 32-54 and column 7, lines 34 and 36.	1-8

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be part of particular relevance

\*E\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*Z\*

document member of the same patent family

Date of the actual completion of the international search

17 FEBRUARY 1996

Date of mailing of the international search report

27 FEB 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RAYMOND J. HENLEY III

Telephone No. (703) 308-1235